Automate Your Wheel Strategy on BFRIW
With Tiblio's Option Bot, you can configure your own wheel strategy including BFRIW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BFRIW
- Rev/Share 4.2811
- Book/Share 0.0529
- PB 19.6778
- Debt/Equity 10.3689
- CurrentRatio 1.399
- ROIC -2.695
- MktCap 10544110.0
- FreeCF/Share -1.2416
- PFCF -0.957
- PE -0.8008
- Debt/Assets 0.2932
- DivYield 0
- ROE -2.16
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Biofrontera Inc. (BFRIW)
- IPO Date 2021-10-29
- Website https://www.biofrontera-us.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Hermann Luebbert
- Employees 92
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.